Shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) ended Wednesday session in red amid volatile trading. The shares closed down -0.15 points or -0.54% at $27.38 with 19.43 million shares getting traded. Post opening the session at $27.60, the shares hit an intraday low of $27.11 and an intraday high of $28.05 and the price vacillated in this range throughout the day. The company has a market cap of $8.99 billion and the numbers of outstanding shares have been calculated to be 341.19 million shares.
Valeant Pharmaceuticals Intl Inc (VRX) on Aug. 22, 2016 announced that Paul S. Herendeen has been appointed Executive Vice President, Finance and will take over the role of Chief Financial Officer from Robert L. Rosiello effective immediately. Mr. Rosiello will remain at Valeant as Executive Vice President, Corporate Development and Strategy.
Mr. Herendeen has more than 30 years of broad financial experience and leadership, including 16 years as CFO of Warner Chilcott and MedPointe. He joins Valeant from Zoetis, where he served as Executive Vice President and CFO for the past two years. As Valeant CFO, he will oversee all of the company’s finance functions, including: controllership, tax, and treasury, reporting directly to chief executive officer Joseph C. Papa .
“Paul is an accomplished and well respected financial executive, and we are delighted to welcome him to Valeant,” said Mr. Papa. “His prior experience as a public company CFO, strong operational focus and disciplined approach to financial management make him the ideal choice to lead our finance function as we execute on our plans to stabilize and transform the company. As we move forward, Paul and the other members of the executive management team will play vital roles in shaping the new Valeant.”
Mr. Herendeen stated, “I am pleased to bring my experience and financial expertise to Valeant at this important point in its transformation, and I look forward to working with the leadership team and my finance colleagues to contribute to the company’s future success.”
In his new role, Mr. Rosiello will assume responsibility for Corporate Development and Strategy and continues as EVP and an Executive Committee member, reporting directly to Joe Papa .
“I consider Rob Rosiello a trusted colleague,” said Mr. Papa. “At a critical time, he led our team through a financial restatement, oversaw the process of becoming current in our SEC filings, and spearheaded our efforts to strengthen our finance team, particularly by recruiting a new chief accounting officer. Rob’s integrity, work ethic and business acumen will be assets as we further develop our strategies to improve people’s lives with our healthcare products.”
Shares of Pfizer Inc. (NYSE:PFE) ended Wednesday session in red amid volatile trading. The shares closed down -0.10 points or -0.29% at $33.94 with 18.90 million shares getting traded. Post opening the session at $34.12, the shares hit an intraday low of $33.86 and an intraday high of $34.35 and the price vacillated in this range throughout the day. The company has a market cap of $202.24 billion and the numbers of outstanding shares have been calculated to be 6.07 billion shares.
Pfizer Inc. (PFE) on September 13, 2016 announced it has launched a new app, Moodivator, to help motivate and encourage the millions of adults who experience depression. Depression is one of the most common mental health disorders in the United States, as an estimated one in 15 adults (6.7%) experience at least one major depressive episode in any given year.
Living with depression can feel isolating, overwhelming and impact all aspects of a person’s life. An increasing number of patients, especially those who suffer from chronic conditions like depression, are turning to their smartphones to supplement treatment they receive. The new app aims to provide ongoing motivation in a simple and portable way. Moodivator is designed to help complement the treatment patients receive by allowing them to track their mood, set goals and establish routines that can help support them in their daily life. The Moodivator app is free and available to download for iPhones from the Apple App Store at https://itunes.apple.com/us/app/moodivator/id1103213442?ls=1&mt=8.
Treatment for depression often includes a number of approaches such as talk therapy, medication, peer support and a personal wellness plan – however, it may be challenging for some patients to adhere to their treatment. Fortunately, advances in technology like Moodivator are offering new ways to approach health management, encouraging them to take a more active role in managing their condition. In fact, a 2014 survey found that 70% of patients being treated for a mental health disorder say they want to use a mobile application to monitor their mental health on a daily basis.
“As awareness of the magnitude and severity of depression continues to mount, technology like the Moodivator app represents a new and exciting frontier for helping people with depression. The option to set, track and achieve personal goals in the Moodivator app ties in nicely with cognitive behavioral therapy techniques that I use often with my patients,” said Susan Kornstein, MD, professor of psychiatry at Virginia Commonwealth University School of Medicine, who helped consult on the app’s design. “The opportunity for patients to track and export their mood and goal progress in easy-to-read charts is also very useful, because the progress can then be shared with doctors to help inform care decisions.”